Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse
Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/
Brisbane Airport
Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis.
Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand.
“Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to consolidate and accelerate digitization, leading to improved decision-making and operational performance.
"Our data will be a crucial asset in driving efficiency and elevating the traveler experience at Brisbane Airport."
Ryan Both, Brisbane Airport Executive General Manager Aviation said: “Accessing Cirium’s schedules data through Cirium Sky Warehouse enables advanced automation, marking a critical step in Brisbane Airport’s digital transformation project.”
“The schedules data plays a critical role in creating and executing more accurate flight schedules, planning for future events and fluctuations in air traffic, gaining more comprehensive insights, and making decisions for business growth. This will lead to numerous improvements around efficiency, sustainability and passenger experience.”
“Embracing a cloud-based data integration approach also means we will significantly reduce the time spent internally on data and ultimately drive cost efficiencies.”
Brisbane Airport is currently undergoing a transformation program known as Future BNE, which includes 150 projects over a 10-year period, focusing on upgrades to the airport’s domestic and international terminals, as well as planning for a third terminal, ahead of the city hosting the 2032 Olympics.
This first phase modernization will support an improved experience for the almost 25 million passengers currently passing through its terminals and the additional 10 million expected over the coming decade.
The Cirium Sky Warehouse delivers the highest quality aviation data and analytics in one accessible data cloud, aligning seamlessly with Brisbane Airport’s digital transformation objectives. While the airport will initially leverage schedules data, a wealth of other data can be accessed and integrated from Cirium Sky Warehouse including flight, traffic, fleet, fares, weather, and CO2 emissions.
By leveraging the power of Cirium’s data cloud, Brisbane Airport joins global major airlines, fuel supply companies, aviation financiers, and more in enhancing its planning, operational efficiency and growth opportunities.
Notes to editors
To find out more about the Cirium Sky Warehouse, click here.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth. Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. For further information please follow Cirium on LinkedIn or visit cirium.com.
About Brisbane Airport
BNE is the third-largest airport in Australia by passenger numbers, with 24 million passengers travelling through the airport annually. BNE contributes $4.7 billion GDP annually, with 1 in 70 Queensland jobs enabled by BNE and benefits provided range of key industries such as tourism, resources and international education. BNE is the largest airport in Australia by land size, covering 2,700 hectares of land used for aviation, property development and consumer businesses, which employ over 20,000 people. In 2025 it celebrates 100 years of operation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317052819/en/
Contacts
For Cirium media inquiries please contact media@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 08:00:00 EET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 08:00:00 EET | Press release
Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asgar MD, Dr Samir Kapadia MD, and Dr Nicolas van Mieghem MD. The SAB is chaired by Dr Martin Leon, Professor of Medicine at New York’s Columbia University Irving Med
Mark Wiseman appointed Chairman of Alter Domus18.3.2025 07:00:00 EET | Press release
Alter Domus, the leading global provider of tech-enabled fund services for the private equity, real assets and private debt sectors today appointed Mark Wiseman as Chairman. Mr. Wiseman is the former Head of Active Equities and Chairman of BlackRock’s Alternatives Business, as well as President & CEO of Canada Pension Plan Investment Board (CPPIB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317232851/en/ Mark Wiseman Following a successful tenure, René Beltjens will step down as Chairman but will retain his seat on the Board. As alternatives specialists, with $3 trillion assets under administration (AUA), Alter Domus’ end-to-end servicing expertise enables asset managers to focus on investing and creating outsized returns for investors. Alter Domus’ leadership in alternatives and market share growth has been achieved by significant investments in fund administration services and debt capital market solutions. As a tec
Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales17.3.2025 21:37:00 EET | Press release
World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings. After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold. More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility. "This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is on track to supercharge DeFi as it transforms global fin
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product17.3.2025 21:28:00 EET | Press release
RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/ RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege. “The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimisti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom